BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 23247511)

  • 1. IBD: Can TNF inhibitors be administered during the third trimester?
    Nielsen OH; Jess T
    Nat Rev Gastroenterol Hepatol; 2013 Mar; 10(3):130-1. PubMed ID: 23247511
    [No Abstract]   [Full Text] [Related]  

  • 2. Increased hospitalizations in elderly with inflammatory bowel disease on anti-tumor necrosis factor therapy but not increased infections: a community practice experience.
    Shen H; Lipka S; Katz S
    J Crohns Colitis; 2014 Aug; 8(8):898-9. PubMed ID: 24434182
    [No Abstract]   [Full Text] [Related]  

  • 3. Molecular mechanisms of action of anti-TNF-α agents - Comparison among therapeutic TNF-α antagonists.
    Mitoma H; Horiuchi T; Tsukamoto H; Ueda N
    Cytokine; 2018 Jan; 101():56-63. PubMed ID: 27567553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The classics in perspective.
    Panés J; Ghosh S
    Gut; 2007 Sep; 56(9):1184-6. PubMed ID: 17698863
    [No Abstract]   [Full Text] [Related]  

  • 5. [Anti-tumor necrosis factor-α medications and pregnancy].
    Simon PC; Vallano A
    Med Clin (Barc); 2013 Sep; 141(6):257-9. PubMed ID: 23702347
    [No Abstract]   [Full Text] [Related]  

  • 6. Anti TNF-alpha treatment for Crohn' disease: "ménage a trois".
    Danese S
    Curr Drug Targets; 2010 Feb; 11(2):136-7. PubMed ID: 20214597
    [No Abstract]   [Full Text] [Related]  

  • 7. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series.
    Afzali A; Wheat CL; Hu JK; Olerud JE; Lee SD
    J Crohns Colitis; 2014 Jun; 8(6):480-8. PubMed ID: 24268978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-analysis: peri-operative anti-TNFα treatment and post-operative complications in patients with inflammatory bowel disease.
    Narula N; Charleton D; Marshall JK
    Aliment Pharmacol Ther; 2013 Jun; 37(11):1057-64. PubMed ID: 23581515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-tumor necrosis factor agents and placental transfer: relevant clinical data for rational decision-making.
    Kane S
    Clin Gastroenterol Hepatol; 2013 Mar; 11(3):293-4. PubMed ID: 23247325
    [No Abstract]   [Full Text] [Related]  

  • 10. Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-α therapy in inflammatory bowel disease.
    Williams CJ; Peyrin-Biroulet L; Ford AC
    Aliment Pharmacol Ther; 2014 Mar; 39(5):447-58. PubMed ID: 24444171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of extraintestinal solid cancer with anti-TNF therapy in adults with inflammatory bowel disease: review of the literature.
    Hudesman D; Lichtiger S; Sands B
    Inflamm Bowel Dis; 2013 Mar; 19(3):644-9. PubMed ID: 23314243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [TNF-alpha blocking therapy in chronic inflammatory bowel disease].
    Molnár T
    Orv Hetil; 2009 Sep; 150(38):1773-9. PubMed ID: 19740722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of the tumor necrosis factor antagonists in the treatment of inflammatory bowel disease: an update.
    Leso V; Leggio L; Armuzzi A; Gasbarrini G; Gasbarrini A; Addolorato G
    Eur J Gastroenterol Hepatol; 2010 Jul; 22(7):779-86. PubMed ID: 19786877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Safety and effectiveness of biologics in treating inflammatory bowel diseases in pregnancy].
    Tursi A
    Recenti Prog Med; 2010 Oct; 101(10):396-401. PubMed ID: 21137576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-nuclear antibody positivity and the use of certolizumab in inflammatory bowel disease patients who have had arthralgias or lupus-like reactions from infliximab or adalimumab.
    Verma HD; Scherl EJ; Jacob VE; Bosworth BP
    J Dig Dis; 2011 Oct; 12(5):379-83. PubMed ID: 21955431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
    Behm BW; Bickston SJ
    Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor necrosis factor blockade for treatment of inflammatory bowel disease: efficacy and safety.
    Ngo B; Farrell CP; Barr M; Wolov K; Bailey R; Mullin JM; Thornton JJ
    Curr Mol Pharmacol; 2010 Nov; 3(3):145-52. PubMed ID: 20799925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-TNF-alpha treatment strategies: results and clinical perspectives.
    D'Haens G
    Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S209-16. PubMed ID: 20117344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of biologic agents in pregnancy and breastfeeding.
    Horst S; Kane S
    Gastroenterol Clin North Am; 2014 Sep; 43(3):495-508. PubMed ID: 25110255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Current status of new drug development for inflammatory bowel diseases].
    Kohgo Y; Tanabe H; Fujiya M
    Nihon Rinsho; 2012 Feb; 70 Suppl 1():378-82. PubMed ID: 23126121
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.